Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies
Curtis A. Lachowiez, Sanam Loghavi, Zhihong Zeng, et al.
Blood Cancer Discovery (2023) Vol. 4, Iss. 4, pp. 276-293
Open Access | Times Cited: 71

Showing 26-50 of 71 citing articles:

Selecting optimal therapy for higher-risk myelodysplastic syndromes: present and future projections
Farzad Teymouri, Constantin A Dasanu
Expert Opinion on Pharmacotherapy (2025)
Open Access
Will Triplet Therapy Become Standard of Care in Acute Myeloid Leukemia?
Yuchen Liu, Yasmin Abaza, Jessica K. Altman
Advances in Oncology (2025)
Closed Access
Recent Developments in Differentiation Therapy of Acute Myeloid Leukemia
Ugo Testa, Germana Castelli, Elvira Pelosi
Cancers (2025) Vol. 17, Iss. 7, pp. 1141-1141
Open Access
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients
Christophe Willekens, Alexandre Bazinet, Samy Chraïbi, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access
Rare Genetic and Uncommon Morphological Entities in Adults with Acute Myeloid Leukemia
Xavier Thomas
Current Oncology Reports (2025)
Closed Access
Leucémies aigües myéloïdes avec mutations IDH1/2
Ludovic Gabellier, Enzo Bosetta, Maël Heiblig, et al.
médecine/sciences (2025) Vol. 41, Iss. 4, pp. 355-366
Open Access
Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents
Danielle Hammond, Sanam Loghavi, Sa A. Wang, et al.
Blood Cancer Journal (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 9
Targeting regulated cell death (RCD) in hematological malignancies: Recent advances and therapeutic potential
Yu Zhang, Xiangxiang Zhou
Biomedicine & Pharmacotherapy (2024) Vol. 175, pp. 116667-116667
Open Access | Times Cited: 3
Mitochondrial bioenergetics as a cell fate rheostat for responsive to Bcl-2 drugs: New cues for cancer chemotherapy
Charlotte Palominos, Sebastián Fuentes-Retamal, Juan Pablo Salazar, et al.
Cancer Letters (2024) Vol. 594, pp. 216965-216965
Closed Access | Times Cited: 3
Novel insights and therapeutic approaches in secondary AML
Giovanni Marconi, Michela Rondoni, Beatrice Anna Zannetti, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 3
Precision medicine in AML: overcoming resistance
Samuel Urrutia, Koichi Takahashi
International Journal of Hematology (2024) Vol. 120, Iss. 4, pp. 439-454
Closed Access | Times Cited: 3
Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies
Pasquale Niscola, Valentina Gianfelici, Gianfranco Catalano, et al.
Current Oncology (2024) Vol. 31, Iss. 11, pp. 6632-6658
Open Access | Times Cited: 3
Mechanisms of Resistance to Small Molecules in Acute Myeloid Leukemia
Tonio Johannes Lukas Lang, Frédérik Damm, Lars Bullinger, et al.
Cancers (2023) Vol. 15, Iss. 18, pp. 4573-4573
Open Access | Times Cited: 8
IDH1/2 inhibitor monotherapy in blast‐phase myeloproliferative neoplasms: A multicentre experience
Naseema Gangat, Helen Ajufo, Maymona Abdelmagid, et al.
British Journal of Haematology (2023) Vol. 203, Iss. 3
Closed Access | Times Cited: 7
The future paradigm of HMA + VEN or targeted inhibitor approaches: sequencing or triplet combinations in AML therapy
Sangeetha Venugopal, Justin M. Watts
Hematology (2023) Vol. 2023, Iss. 1, pp. 192-197
Closed Access | Times Cited: 7
Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go?
Jennifer Marvin‐Peek, Jason S. Gilbert, Daniel A. Pollyea, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 9, pp. 1790-1801
Closed Access | Times Cited: 2
Common Driver Mutations in AML: Biological Impact, Clinical Considerations, and Treatment Strategies
Tiffany Nong, Shefali Mehra, Justin Taylor
Cells (2024) Vol. 13, Iss. 16, pp. 1392-1392
Open Access | Times Cited: 2
Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations
Rabia Shahswar, Arnold Ganser
Expert Review of Hematology (2024) Vol. 17, Iss. 10, pp. 723-739
Closed Access | Times Cited: 2
Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm
Stéphane de Botton, Christian Récher, Jorge E. Cortés, et al.
British Journal of Haematology (2024)
Open Access | Times Cited: 2
Azacitidine–venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients
Claire Petit, C. Saillard, Bilal Mohty, et al.
European Journal Of Haematology (2023) Vol. 112, Iss. 4, pp. 530-537
Open Access | Times Cited: 5
The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches
Emily Gruber, Lev M. Kats
Biochemical Society Transactions (2023) Vol. 51, Iss. 4, pp. 1675-1686
Open Access | Times Cited: 4
Test Then Erase? Current Status and Future Opportunities for Measurable Residual Disease Testing in Acute Myeloid Leukemia
Amanda Blackmon, Christopher S. Hourigan
Acta Haematologica (2023) Vol. 147, Iss. 2, pp. 133-146
Open Access | Times Cited: 4
Venetoclax in the treatment of acute myeloid leukemia: Beyond VIALE‐A
Naseema Gangat, Ayalew Tefferi
American Journal of Hematology (2024) Vol. 99, Iss. 4, pp. 515-518
Open Access | Times Cited: 1
Immunotherapeutic Potential of Mutated NPM1 for the Treatment of AML
Jochen Greiner, Eithar Mohamed, Daniel Fletcher, et al.
(2024)
Open Access | Times Cited: 1
Clinical management of patients diagnosed with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents after achieving a response: a real-life study
Carlos Jiménez‐Vicente, Ares Guardia-Torrelles, Amanda Isabel Pérez‐Valencia, et al.
Annals of Hematology (2024) Vol. 103, Iss. 10, pp. 4033-4043
Open Access | Times Cited: 1

Scroll to top